---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-007713"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:31:50.831570+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Phio reports Phase 1b data: complete & partial responses in cutaneous SCC patients

## Summary
- Intratumoral PH-762 well tolerated with no related adverse events or dose-limiting toxicities across 5 patients.
- Cohort 2: 1 complete response (100% tumor clearance) and 1 partial response (90% tumor clearance) in cutaneous squamous cell carcinoma.
- Phase 1b trial ongoing; enrollment anticipated to complete in Q3 2025.
- Data presented at SITC 2024 annual meeting in Houston, TX.

## SEC filing metadata
- accession: 0001683168-24-007713
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316824007713/0001683168-24-007713-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316824007713/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-007713
- JSON: https://secwatch.observer/filing/0001683168-24-007713.json
- Plain text: https://secwatch.observer/filing/0001683168-24-007713.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.